Skip to content

Boris B. Quednow

45 papers in the library · 1,535 citations · publishing 2004-2026

Papers

Sort Most recent Most cited

Combined DMT-harmine formulation reduces negative self-referential emotions during social self-evaluation: a randomized placebo-controlled trial in healthy volunteers.

Psychopharmacology July 14, 2026 Helena Aicher, Joëlle Dornbierer, Luzia Caflisch et al.

Negative self-referential emotions such as embarrassment and shame play a key role in the psychopathology of psychiatric disorders but are often insufficiently addressed by standard treatments. Psychedelics such as ayahuasca - an Amazonian plant decoction containing the psychedelic N,N-dimethyltryptamine (DMT) and harmala alkaloids, have been proposed to positively modulate self-referential...

DOI: 10.1007/s00213-026-07118-4 (opens in new tab) Full text (opens in new tab) Embarrassment Hallucinogens Harmine N,N-Dimethyltryptamine +3

Global increases in brain glucose metabolism following acute N,N-dimethyltryptamine and harmine administration in healthy volunteers: A randomised [18F]FDG-PET study.

Journal of Cerebral Blood Flow & Metabolism June 1, 2026 Klemens Egger, Robert Bozsak, Helena Aicher et al.

Classical psychedelics such as N,N-dimethyltryptamine (DMT) modulate consciousness via serotonergic receptor agonism, and are increasingly investigated for their psychotherapeutic potential. When combined with the monoamine oxidase A (MAO-A) inhibitor harmine-mimicking the pharmacological profile of ayahuasca-oral DMT induces a psychedelic experience lasting 4-5 h. While some neuroimaging...

Global increases in brain glucose metabolism following acute N,N-dimethyltryptamine and harmine administration in healthy volunteers: A randomised [ 18 F]FDG-PET study

Universität Zürich, ZORA June 1, 2026 Klemens Egger, Robert Bozsak, Helena Aicher et al.

Classical psychedelics such as N,N -dimethyltryptamine (DMT) modulate consciousness via serotonergic receptor agonism, and are increasingly investigated for their psychotherapeutic potential. When combined with the monoamine oxidase A (MAO-A) inhibitor harmine—mimicking the pharmacological profile of ayahuasca—oral DMT induces a psychedelic experience lasting 4–5 h. While some neuroimaging...

DOI: 10.5167/uzh-434709 (opens in new tab) Harmine Placebo Neuroimaging Metabolite +9

Differential alterations in peripheral tryptophan pathways in methamphetamine versus MDMA users are linked to their contrasting psychiatric symptoms.

Translational Psychiatry May 21, 2026 Francesco Bavato, Andrea E. Steuer, Anna M. Jacobsen et al.

Methamphetamine (METH, "Crystal Meth") and 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") are two types of substituted amphetamines that share structural-chemical similarities but exhibit contrasting acute and chronic effects including addictive liability. Tryptophan (TRY) pathways are involved in pleiotropic physiological functions at the interface of brain-body connections. Preclinical...

A systematic review of pharmacological effects on human aversive memory.

Neuroscience & Biobehavioral Reviews April 1, 2026 Yanfang Xia, Boris B. Quednow, Dominik R Bach

A large body of work has investigated the effect of various pharmacological compounds on aversive memory formation, retrieval, and modification in humans. A broad overview across signalling pathways and memory models is currently lacking. Here, we systematically review publications that tested the impact of acute pharmacological interventions on aversive memory in healthy humans, following...

DOI: 10.1016/j.neubiorev.2026.106548 (opens in new tab) Full text (opens in new tab) Aversive memory Fear memory Pharmacological intervention Systematic review

Global increases in brain glucose metabolism following acute N,N-dimethyltryptamine and harmine administration in healthy volunteers: A randomised [¹⁸F]FDG-PET study

Repository for Publications and Research Data 2026 Klemens Egger, Robert Bozsak, Helena Aicher et al.

Classical psychedelics such as N,N-dimethyltryptamine (DMT) modulate consciousness via serotonergic receptor agonism, and are increasingly investigated for their psychotherapeutic potential. When combined with the monoamine oxidase A (MAO-A) inhibitor harmine—mimicking the pharmacological profile of ayahuasca—oral DMT induces a psychedelic experience lasting 4–5 h. While some neuroimaging...

DOI: 10.3929/ethz-c-000801722 (opens in new tab) Harmine Placebo Neuroimaging Metabolite +9

Memory deficits of MDMA users are linked to cortical thinning related to 5-HT receptor densities

Brain October 19, 2025 Rebecca C Coray, Vincent Beliveau, Josua Zimmermann et al. 1 citation

Regular recreational use of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") has been consistently linked to verbal memory dysfunctions, whose neurobiological origins remain unclear. Although neurochemical, structural, and functional alterations resulting from repeated MDMA intake have been identified in user populations, only limited knowledge exists regarding potential interrelationships...

Cannabis use is associated with changes in psychological and functional well-being during young adulthood: evidence from self-reports and hair analyses.

Psychological Medicine August 26, 2025 Lydia Johnson-Ferguson, Michelle Loher, Laura Bechtiger et al. 2 citations

Cannabis use in young adulthood is common, yet few studies have explored how it predicts changes in psychopathology and functional well-being in community samples. We assessed these links using both self-reported frequency of cannabis use and hair THC concentrations. Data came from a community sample of young adults (N = 863) who reported cannabis use (weekly-to-daily use: n = 150) and provided...

Global Increases in Brain Glucose Metabolism Following Acute N,N-Dimethyltryptamine and Harmine Administration in Healthy Volunteers: An [¹⁸F]FDG-PET Study

Research Square July 27, 2025 Klemens Egger, Robert Bozsak, Helena Aicher et al. 1 citation preprint

Abstract Classical psychedelics such N,N -dimethyltryptamine (DMT), psilocybin, and lysergic acid diethylamide (LSD) modulate consciousness via serotonergic receptor agonism, and are increasingly investigated for their psychotherapeutic potential. When combined with the monoamine oxidase A (MAO-A) inhibitor harmine—mimicking the pharmacological profile of ayahuasca—oral DMT induces a...

DOI: 10.21203/rs.3.rs-7099164/v1 (opens in new tab) N-dimethyltryptamine Psychoactive compounds n Harmine Brain activity +6

Inhalational nitrous oxide as a transdiagnostic approach for the treatment of suicidal ideation and suicidality in psychiatric inpatients: protocol for a double-blind randomised, controlled clinical single-centre trial.

BMJ Open July 16, 2025 Golo Kronenberg, Anna Bankwitz, Barbora Provaznikova et al.

Suicidal thoughts and behaviours are linked to a wide range of mental health conditions. New interest in the psychiatric benefits of nitrous oxide (N2O) has only recently emerged. The broad pharmacological effects of N2O are thought to be due in large part to N-methyl-d-aspartate antagonism and opioid effects. The purpose of this study protocol is to test whether inhalational N2O exerts rapid...

DOI: 10.1136/bmjopen-2024-096825 (opens in new tab) Full text (opens in new tab) Clinical pharmacology Psychometrics Suicide & self-harm

Examining the pharmacokinetic and pharmacodynamic interaction of N,N-dimethyltryptamine and harmine in healthy volunteers: Α factorial dose-escalation study.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie March 1, 2025 Klemens Egger, Javier Jareño Redondo, Jovin Müller et al. 14 citations

Ayahuasca, a traditional psychoactive Amazonian brew, usually contains N,N-dimethyltryptamine (DMT) and β-carboline (harmine, harmaline, tetrahydroharmine) monoamine oxidase inhibitors. However, the pharmacological interactions between these compounds remain incompletely understood. In this study, we developed an ayahuasca-inspired formulation containing DMT and harmine, aiming to...

Pharmacokinetics and pharmacodynamics of an innovative psychedelic N,N-dimethyltryptamine/harmine formulation in healthy participants: a randomized controlled trial.

The International Journal of Neuropsychopharmacology December 28, 2024 Michael J Mueller, Helena Aicher, Dario Dornbierer et al. 10 citations

Recent interest in the clinical use of psychedelics has highlighted plant-derived medicines like ayahuasca showing rapid-acting and sustainable therapeutic effects in various psychiatric conditions. This traditional Amazonian plant decoction contains N,N-dimethyltryptamine (DMT) and β-carboline alkaloids such as harmine. However, its use is often accompanied by distressing effects like nausea,...

[Psychedelic and dissociative agents in psychiatry: challenges in the treatment].

Der Nervenarzt September 1, 2024 Johannes Jungwirth, Francesco Bavato, Boris B. Quednow 6 citations

With the discovery of the antidepressive effects of ketamine and the increasing withdrawal of the pharmaceutical industry from the development of new psychotropic drugs, the psychiatric research into the clinical application of hallucinogens in psychiatry has literally blossomed in the last two decades. Promising results for various treatment approaches with psychedelic agents, such lysergic...

DOI: 10.1007/s00115-024-01727-0 (opens in new tab) Full text (opens in new tab) Psychedelic therapy Mental health treatment Clinical safety Addictive potential +5

Chemical cousins with contrasting behavioural profiles: MDMA users and methamphetamine users differ in social-cognitive functions and aggression.

European Neuropsychopharmacology June 1, 2024 Amelie Zacher, Josua Zimmermann, David M. Cole et al. 10 citations

Methamphetamine (METH, "Crystal Meth") and 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") share structural-chemical similarities but have distinct psychotropic profiles due to specific neurochemical actions. Previous research has suggested that their impact on social cognitive functions and social behaviour may differ significantly, however, direct comparisons of METH and MDMA users...

Conflict monitoring and emotional processing in 3,4-methylenedioxymethamphetamine (MDMA) and methamphetamine users - A comparative neurophysiological study.

NeuroImage: Clinical 2024 Antje Opitz, Josua Zimmermann, David M. Cole et al. 2 citations

In stimulant use and addiction, conflict control processes are crucial for regulating substance use and sustaining abstinence, which can be particularly challenging in social-affective situations. Users of methamphetamine (METH, "Ice") and 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") both experience impulse control deficits, but display different social-affective and addictive profiles....

Substance use in sexual minority youth: prevalence in an urban cohort.

Child and Adolescent Psychiatry and Mental Health September 16, 2023 Florian Vock, Lydia Johnson-Ferguson, Laura Bechtiger et al. 3 citations

Little comparative data on substance use (SU) between sexual minority youth (SMY) and heterosexual youth (HET) is available. This study compares the prevalence of SU in an urban cohort between SMY and HET and evaluates demographic and psychosocial predictors of SU. Data came from a prospective-longitudinal cohort study in an urban setting (N = 1297). SU and psychosocial variables such as...

Striatal Iron Deposition in Recreational MDMA (Ecstasy) Users.

Biological Psychiatry: Cognitive Neuroscience and Neuroimaging September 2023 Rebecca C Coray, Jatta Berberat, Josua Zimmermann et al.

The common club drug MDMA (also known as ecstasy) enhances mood, sensory perception, energy, sociability, and euphoria. While MDMA has been shown to produce neurotoxicity in animal models, research on its potential neurotoxic effects in humans is inconclusive and has focused primarily on the serotonin system. We investigated 34 regular, largely pure MDMA users for signs of premature...

The functional connectome of 3,4‐methyldioxymethamphetamine‐related declarative memory impairments

Human Brain Mapping August 2, 2023 Rebecca C Coray, Josua Zimmermann, Amelie Haugg et al. 5 citations

The chronic intake of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") bears a strong risk for sustained declarative memory impairments. Although such memory deficits have been repeatedly reported, their neurofunctional origin remains elusive. Therefore, we here investigate the neuronal basis of altered declarative memory in recurrent MDMA users at the level of brain connectivity. We...

Chronic 3,4-Methylenedioxymethamphetamine (MDMA) Use Is Related to Glutamate and GABA Concentrations in the Striatum But Not the Anterior Cingulate Cortex.

The International Journal of Neuropsychopharmacology June 1, 2023 Josua Zimmermann, Niklaus Zölch, Rebecca C Coray et al.

Background: 3,4-Methylenedioxymethamphetamine (MDMA) is a widely used recreational substance inducing acute release of serotonin. Previous studies in chronic MDMA users demonstrated selective adaptations in the serotonin system, which were assumed to be associated with cognitive deficits. However, serotonin functions are strongly entangled with glutamate as well as γ-aminobutyric acid (GABA)...

Pharmacokinetic and Pharmacodynamic Interaction of the Ayahuasca Constituents Harmine and Dimethyltryptamine (DMT) in the Rat Brain

January 4, 2023 Klemens Egger, Frederik Gudmundsen, Naja Støckel Jessen et al. preprint

RationaleThe psychedelic effects of the traditional Amazonian botanical decoction known as ayahuasca are attributed to the effects of N,N-dimethyltryptamine (DMT) at brain serotonin 5-HT2A receptors. To make oral DMT bioavailable, ayahuasca additionally contains reversible monoamine oxidase A (MAO-A) inhibitors, namely β-carboline alkaloids such as harmine. However, there is lacking biochemical...

DOI: 10.31219/osf.io/cv6ey (opens in new tab) Ayahuasca Harmine Pharmacology Harmaline +5

A pilot study of cerebral metabolism and serotonin 5-HT2A receptor occupancy in rats treated with the psychedelic tryptamine DMT in conjunction with the MAO inhibitor harmine.

Frontiers in Pharmacology 2023 Klemens Egger, Frederik Gudmundsen, Naja Støckel Jessen et al. 17 citations

Rationale: The psychedelic effects of the traditional Amazonian botanical decoction known as ayahuasca are often attributed to agonism at brain serotonin 5-HT2A receptors by N,N-dimethyltryptamine (DMT). To reduce first pass metabolism of oral DMT, ayahuasca preparations additionally contain reversible monoamine oxidase A (MAO-A) inhibitors, namely β-carboline alkaloids such as harmine....

White matter alterations in chronic MDMA use: Evidence from diffusion tensor imaging and neurofilament light chain blood levels

NeuroImage: Clinical September 19, 2022 Josua Zimmermann, Nicole Friedli, Francesco Bavato et al. 14 citations

3,4–Methylenedioxymethamphetamine (MDMA, “Ecstasy”) is a serotonin- and noradrenaline-releasing substance, currently among the most widely used illicit substances worldwide. In animal studies, repeated exposure to MDMA has been associated with dendritic but also axonal degeneration in the brain. However, translation of the axonal findings, specifically, to humans has been repeatedly questioned...

DOI: 10.1016/j.nicl.2022.103191 (opens in new tab) Full text (opens in new tab) MDMA Neurotoxicity Axonal neuropathology White matter +2

Brain-derived neurotrophic factor protects serotonergic neurons against 3,4-methylenedioxymethamphetamine (“Ecstasy”) induced cytoskeletal damage

Journal of Neural Transmission June 1, 2022 Francesco Bavato, Serena Stamatakos, C. M. Yde Ohki et al.

Abstract3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”) use has been linked to persistent alterations of the brain serotonergic (5-HT) system in animal and human studies, but the molecular underpinnings are still unclear. Cytoskeletal structures such as neurofilament light chain (NfL) are promising markers of drug-induced brain toxicity and may be involved in MDMA neurotoxicity. The...

Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans

Molecules April 22, 2021 Paul Cumming, Milan Scheidegger, Dario Dornbierer et al. 45 citations

Hallucinogens are a loosely defined group of compounds including LSD, N,N-dimethyltryptamines, mescaline, psilocybin/psilocin, and 2,5-dimethoxy-4-methamphetamine (DOM), which can evoke intense visual and emotional experiences. We are witnessing a renaissance of research interest in hallucinogens, driven by increasing awareness of their psychotherapeutic potential. As such, we now present a...

DOI: 10.3390/molecules26092451 (opens in new tab) Action physics Drug action Pharmacology